Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Reviewed by Lily Ramsey, LLMOct 16 2023

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

Small molecule oncology target inhibitors represent the largest part of Insilico's therapeutic pipeline portfolio, which includes 31 programs across 29 targets. The Company recently entered into a licensing deal with Exelixis on its potentially best-in-class generative AI-designed USP1 inhibitor for BRCA-mutant tumors for $80m upfront and additional milestone payments and tiered royalties. That drug is currently in a Phase I clinical trial.

Using our AI platform, we have been able to advance a number of anti-cancer therapeutics that use new mechanisms to stop tumor growth and cancer progression, including two in clinical stage."

Sujata Rao, MD, Chief Medical Officer at Insilico Medicine

Dr. Rao has extensive experience in clinical oncology practice and over 15 years in pharma leading global clinical development for cancer drugs. "Driven by a strategy of focusing on novelty, confidence, and commercial tractability, and designed to meet the high unmet medical needs of patients, we have developed a number of promising anti-cancer assets and look forward to presenting to the leading cancer conferences."

Dr. Rao showcased four of the Company's novel AI-designed cancer inhibitors at the most recent Association for Cancer Research (AACR) annual meeting.

Insilico's upcoming cancer conference presentations include:

• ESMO - Oct. 20-24: At ESMO, Insilico will present data on ISM8207, a novel QPCTL inhibitor for triple negative breast cancer and B-cell non-Hodgkin lymphoma. The small molecule inhibitor, currently being evaluated in a Phase I trial, has demonstrated anti-tumor activity in both hematological tumors and solid tumors in preclinical studies, as well as favorable pharmacokinetics and safety profiles. This molecule is available for licensing partners in the U.S., Europe and Japan.
• SITC - Nov. 1-5: At SITC, Insilico will present data on ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor cancer immunotherapy for multiple tumor types that enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models. It is also being advanced as a possible treatment for Hypophosphatasia.
• SABCS - Dec. 5-9: At SABCS, Insilico will present data on ISM5043, a novel, selective KAT6 inhibitor for the treatment of advanced ER+/HER2- breast cancer - the most common subtype of breast cancer. Current treatment for patients with advanced or metastatic disease is endocrine therapy in combination with CDK4/6 inhibitors but many patients develop resistance to therapy, indicating a huge unmet medical need.

Insilico is advancing new therapeutics using generative AI via its proprietary end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). The platform has produced four drugs that have reached clinical trials, including a lead drug for the devastating chronic lung disease Idiopathic Pulmonary Fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to Phase II trials with patients.

"We're really encouraged by the progress of our diverse pipeline of cancer therapeutics – two of which have progressed into clinical trials," says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. "Our AI can be thought of as a 'Google for targets' that looks at every single small signal from massive datasets all over the world, including our own robotics data. It gives us signals that the target is working in a specific cancer, it already has demonstrated some efficacy, and it is going to be commercially tractable."

Dr. Rao and Insilico's Chief Business Officer Michelle Chen, PhD, along with other business development professionals, will be in attendance at the upcoming conferences. For any interest in licensing or partnerships, please contact: [email protected].